- Associated Press•8 hours ago
U.S. regulators on Tuesday approved the first lower-cost version of Enbrel, a blockbuster anti-inflammatory drug from Amgen that is among the top-selling drugs in the world.
- The Wall Street Journal•8 hours ago
Novartis lower-priced replica of Amgen’s rheumatoid arthritis and psoriasis drug Enbrel has been approved in the U.S. to treat multiple inflammatory diseases, the company said.
- Market Realist•8 hours ago
StrataGraft, if approved, will be the first biological off-the-shelf skin substitute for treating severe burns.
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||170.08 x 100|
|Ask||170.70 x 100|
|Day's Range||170.12 - 171.94|
|52wk Range||130.09 - 176.64|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.47|
|Avg Vol (3m)||2,884,598|
|Dividend & Yield||4.00 (2.33%)|